Konishi Kazuya, Hasegawa Naoto, Kaneko Hiroyuki, Iimura Yasuaki, Shoji Yasuhito, Kawabata Makoto
Department of Surgery, NTT East Corporation Sapporo Hospital, Japan.
Gan To Kagaku Ryoho. 2010 Jan;37(1):111-3.
A 33-year-old woman was referred to our hospital with a complaint of left breast tumor. After examinations, she was diagnosed as invasive ductal carcinoma with sternum metastasis (T2N0M1(OSS), Stage IV). The tumor was hormone receptor- positive and HER2-negative. Primary systemic chemotherapy with FEC was performed. After four courses, the efficacy was judged as a partial response (PR). After chemotherapy, endocrine therapy with goserelin and tamoxifen was performed. The efficacy of endocrine therapy was as good as that of chemotherapy. After endocrine therapy for 13 months, breast conserving-surgery was performed. After surgery, radiotherapy for left breast and sternum was performed. She continues to undergo outpatient endocrine therapy with no detectable tumor. It is suggested that neoadjuvant endocrine therapy may be useful with consideration for treatment effectiveness and the patient's quality of life.
一名33岁女性因左乳肿瘤主诉转诊至我院。经检查，她被诊断为伴有胸骨转移的浸润性导管癌（T2N0M1(OSS)，IV期）。肿瘤激素受体阳性，HER2阴性。采用FEC方案进行了一线全身化疗。四个疗程后，疗效判定为部分缓解（PR）。化疗后，采用戈舍瑞林和他莫昔芬进行内分泌治疗。内分泌治疗的疗效与化疗相当。内分泌治疗13个月后，进行了保乳手术。术后，对左乳和胸骨进行了放疗。她继续接受门诊内分泌治疗，未检测到肿瘤。考虑到治疗效果和患者生活质量，新辅助内分泌治疗可能是有效的。
